Investing in Aeglea BioTherapeutics Inc. [AGLE]: What You Must Know


Aeglea BioTherapeutics Inc.’s recent filing unveils that its Director Souza Marcio acquired Company’s shares for reported $50472.0 on Aug 25. In the deal valued at $0.56 per share,90,000 shares were bought. As a result of this transaction, Souza Marcio now holds 90,000 shares worth roughly $ 99900.00000000001.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Then, Hanley Jr. Michael Conick bought 28,200 shares, generating $20,022 in total proceeds. Upon buying the shares at $0.71, the Chief Commercial Officer now owns 36,200 shares.

Before that, Quinn Anthony G. bought 80,079 shares. Aeglea BioTherapeutics Inc. shares valued at $187,705 were divested by the President & CEO at a price of $2.34 per share. As a result of the transaction, Quinn Anthony G. now holds 550,540 shares, worth roughly $0.61 million.

Piper Sandler initiated its Aeglea BioTherapeutics Inc. [AGLE] rating to an Overweight in a research note published on Friday, May 04, 2020; the price target was $12. PT values the company’s stock at a premium of 90.75 to its Friday closing price. A number of analysts have revised their coverage, including JP Morgan’s analysts, who began to cover the stock in late March with a ‘”an Overweight”‘ rating. Wells Fargo also remained covering AGLE and has decreased its forecast on September 04, 2018 with a “Market perform” recommendation from previously “an Outperform” rating. Evercore ISI started covering the stock on April 24, 2018. It rated AGLE as “an Outperform”.

Price Performance Review of AGLE

On Friday, Aeglea BioTherapeutics Inc. [NASDAQ:AGLE] saw its stock fall -2.63% to $1.11. On the same session, the stock had its day’s lowest price of $1.05, but rose to a high of $1.19. Over the last five days, the stock has gained 20.65%. Aeglea BioTherapeutics Inc. shares have fallen nearly -76.63% since the year began. Nevertheless, the stocks have fallen -85.51% over the past one year. While a 52-week high of $7.94 was reached on 01/03/22, a 52-week low of $0.37 was recorded on 08/02/22. SMA at 50 days reached $0.5725, while 200 days put it at $1.4278. A total of 0.66 million shares were traded, compared to the trading of 2.56 million shares in the previous session.

Levels Of Support And Resistance For AGLE Stock

The 24-hour chart illustrates a support level at 1.0433, which if violated will result in even more drops to 0.9767. On the upside, there is a resistance level at 1.1833. A further resistance level may holdings at 1.2567. The Relative Strength Index (RSI) on the 14-day chart is 76.47, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.4007, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 35.82%. Stochastics %K at 68.82% indicates the stock is a holding.

How much short interest is there in Aeglea BioTherapeutics Inc.?

A steep rise in short interest was recorded in Aeglea BioTherapeutics Inc. stocks on Jul 14, 2022, dropping by -1.59 million shares to a total of 1.02 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 2.61 million shares. There was a decline of -155.88%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 1.79% of the overall stock float, the days-to-cover ratio (short ratio) fell to 1.82.

Aeglea BioTherapeutics Inc. [AGLE] – Who Are The Largest Shareholders?

In filings from Pictet Asset Management SA, it is revealed that the company now owns 4,890,502 shares, or roughly 8.00% of the outstanding AGLE shares. In other words, the investor’s shares have risen by 2,338,068 from its previous 13-F filing of 2552434.0. Additionally, Sio Capital Management LLC increased 435.94% of its stake after which the total value it holdings stand at $2,455,650. Over the last quarter, Nantahala Capital Management LLC purchased 676,718 shares of Aeglea BioTherapeutics Inc., while Baker Bros. Advisors LP bought 0 shares. At present, Rock Springs Capital Management L is holding 3,072,034 shares valued at $1.62 million. Great Point Partners LLC owned 2,500,000 shares of the company at the time of its most recent 13F filing, worth $1.31 million.

According to FactSet, Aeglea BioTherapeutics Inc.’s share price will average $2.75 in the next year, based on opinions of analysts polled by the firm. This is up nearly 119.3 percent from its previous closing price of $1.14. Analysts expect Aeglea BioTherapeutics Inc. stock to reach the higher price of $6.00, while the lowest price estimate is $1.00. However, 6 analysts have rated AGLE stock as a Buy in their predictions for 2022. The most recent change occurred on March 14, 2018 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $12.


Please enter your comment!
Please enter your name here